Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

休市中 12-05 16:00:00 EST

38.55

-0.02

-0.05%

盘后38.70

+0.15+0.39%

19:59 EST

最高39.48	最低38.05	成交量274.59万
今开38.34	昨收38.57	日振幅3.71%
总市值43.58亿	流通市值42.40亿	总股本1.13亿
成交额1.06亿	换手率2.50%	流通股本1.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":38.55,"timestamp":1764968400000,"preClose":38.57,"halted":0,"volume":2745931,"hourTrading":{"tag":"盘后","latestPrice":38.6999,"preClose":38.55,"latestTime":"19:59 EST","volume":36153,"amount":1394572.2608,"timestamp":1764982778068},"delay":0,"floatShares":109980302,"shares":113036344,"eps":-2.119536,"marketStatus":"休市中","change":-0.02,"latestTime":"12-05 16:00:00 EST","open":38.34,"high":39.48,"low":38.05,"amount":106363272.076177,"amplitude":0.037075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.119536,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":38.57,"preHourTrading":{"tag":"盘前","latestPrice":38.4,"preClose":38.57,"latestTime":"09:29 EST","volume":25184,"amount":980780.982688,"timestamp":1764944954339},"postHourTrading":{"tag":"盘后","latestPrice":38.6999,"preClose":38.55,"latestTime":"19:59 EST","volume":36153,"amount":1394572.2608,"timestamp":1764982778068},"volumeRatio":1.0072144900382736,"optionData":{"bulkOrders":[{"symbol":"VKTX","call":false,"expireDate":1767330000000,"strike":"37.0","timestamp":1764959680012,"price":3.2,"volume":1829,"amount":585280,"type":"+"},{"symbol":"VKTX","call":true,"expireDate":1768539600000,"strike":"75.0","timestamp":1764959680012,"price":0.45,"volume":1829,"amount":82305,"type":"-"}]},"impliedVol":1.1221,"impliedVolPercentile":0.816},"requestUrl":"/m/hq/s/VKTX/tweets","defaultTab":"tweets","newsList":[{"id":"2585611379","title":"Viking Therapeutics, Inc.盘中异动 临近收盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585611379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585611379?lang=zh_cn&edition=full","pubTime":"2025-11-21 04:47","pubTimestamp":1763671654,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日04时47分，Viking Therapeutics, Inc.股票出现异动，股价大幅下挫5.07%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。消息层面，截至04时47分，《H.C. Wainwright维持Viking Therapeutics买入评级，维持目标价102美元》资讯为影响Viking Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121044735a4afeba0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121044735a4afeba0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","VKTX","BK4539","BK4588","BK4139","BK4585","LENZ","BK4007"],"gpt_icon":0},{"id":"1160513193","title":"维京治疗公司在2025年肥胖周会上展示Vk2735肥胖项目的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1160513193","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160513193?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:06","pubTimestamp":1762430775,"startTime":"0","endTime":"0","summary":"维京治疗公司在2025年肥胖周会上展示了Vk2735肥胖项目的临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4599","BK4585","BK4588","VKTX"],"gpt_icon":0},{"id":"1168925049","title":"Viking Therapeutics股价下跌3.8%，因竞争对手Eli Lilly的GLP-1药丸在糖尿病患者后期试验中显示减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168925049","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168925049?lang=zh_cn&edition=full","pubTime":"2025-08-26 21:49","pubTimestamp":1756216158,"startTime":"0","endTime":"0","summary":"Viking Therapeutics股价下跌3.8%，因竞争对手Eli Lilly的GLP-1药丸在糖尿病患者后期试验中显示减重效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","BK4588","BK4139","BK4585","BK4599"],"gpt_icon":0},{"id":"2561457586","title":"高盛评Viking Therapeutics(VKTX.US)口服药物VK2735试验结果：疗效显著但耐受性存疑 更适用体重维持","url":"https://stock-news.laohu8.com/highlight/detail?id=2561457586","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561457586?lang=zh_cn&edition=full","pubTime":"2025-08-21 16:15","pubTimestamp":1755764136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛本周发布关于Viking Therapeutics近期试验结果的评论报告并提及对礼来的影响。近日，Viking Therapeutics宣布，其口服药物VK2735用于治疗肥胖症的Ⅱ期VENTURE口服给药试验达到主要终点，顶线结果积极。需注意的是，Viking Therapeutics设想患者先以VK2735每周皮下注射进行诱导治疗，以快速达到目标体重，随后可继续维持该方案，或转为每月皮下注射或每日口服方案以帮助维持体重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443895.HKD","LU1868837136.USD","BK4007","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU0251131958.USD","LU2237443622.USD","LENZ","BK4516","BK4139","LU1894683264.USD","LU1894683348.USD","LU2237443549.SGD","LU2471134952.CNY","LU1868836591.USD","LU0742534661.SGD","LU1868837300.USD","IE00BSNM7G36.USD","LU0048573561.USD","LU2237443382.USD","LU0061475181.USD","BK4550","LU1791807156.HKD","LU1868836757.USD","BK4599","LU0106831901.USD","IE0004091025.USD","BK4533","LU2471134879.HKD","LU2471134523.USD","LU1868836914.USD","LU2750360997.AUD","VKTX","IE0004086264.USD","LU0251142724.SGD","LU2750360641.GBP","IE0034235188.USD","LU2237438978.USD","LU0096364046.USD","BK4539","IE0002270589.USD","LU2237443978.SGD","BK4588","LU2237443465.HKD","BK4585","LU2471134796.USD","BK4504","IE00B19Z3581.USD","BK4127","LU1668664300.SGD"],"gpt_icon":1},{"id":"1171424689","title":"异动解读 | 维京治疗公司股价盘中大涨5.05%，肥胖药物试验数据获得积极评价","url":"https://stock-news.laohu8.com/highlight/detail?id=1171424689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171424689?lang=zh_cn&edition=full","pubTime":"2025-08-20 21:35","pubTimestamp":1755696906,"startTime":"0","endTime":"0","summary":"8月20日，生物制药公司维京治疗公司股价在盘中大涨5.05%，引起投资者广泛关注。这一涨幅主要源于该公司最新公布的肥胖药物试验结果获得分析师积极评价。维京治疗公司的实验性减肥药VK2735在一项中期试验中表现出色，帮助患者减轻了12.2%的体重。值得注意的是，17家券商中有15家给予维京治疗公司\"买入\"评级，显示出华尔街对该公司的强烈信心。这一观点进一步增强了投资者对VK2735未来发展潜力的信心，推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":1},{"id":"1160858455","title":"Viking Therapeutics减肥口服药试验结果公布后股价暴跌，但它并非孤例","url":"https://stock-news.laohu8.com/highlight/detail?id=1160858455","media":"老虎资讯综合","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160858455?lang=zh_cn&edition=full","pubTime":"2025-08-20 07:43","pubTimestamp":1755647036,"startTime":"0","endTime":"0","summary":"Viking Therapeutics Inc. 周二宣布，其口服减肥药物在临床试验中显示出疗效 —— 但与规模更大的竞争对手类似，该公司股价随即应声下挫。Viking 的股票在周二暴跌 42%。Viking 表示，其 VK2735 口服减重药物在 13 周治疗后，患者平均减重 12.2%，约 26.6 磅。在最高剂量组中，38% 的患者提前中止治疗，而安慰剂组也有 18% 提前退出。根据 S&P Global Market Intelligence 的会议纪要，Viking 首席执行官 Brian Lian 回应道：“我们注意到在之前的试验中，安慰剂组的停药率有所升高。”","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viking Therapeutics减肥口服药试验结果公布后股价暴跌，但它并非孤例","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"gpt_icon":0},{"id":"2560844145","title":"口服减肥药“翻车” ！Viking Therapeutics Inc.(VKTX.US)股价闪崩42% 空头一夜血赚5.21亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2560844145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560844145?lang=zh_cn&edition=full","pubTime":"2025-08-20 07:18","pubTimestamp":1755645490,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，Viking Therapeutics Inc.创下史上最大股价跌幅，让做空该公司的交易员获得巨额收益，一举扭转了今年以来的亏损局面。根据S3 Partners LLC董事总经理Matthew Unterman的数据，这家生物技术公司周二股价暴跌42%，使空头单日实现5.21亿美元的账面收益。尽管如此，分析师仍看好Viking Therapeutics股价，近90%的分析师给予相当于“买入”的评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1331851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4585","VKTX","BK4539","LENZ","BK4139","BK4588","BK4599"],"gpt_icon":1},{"id":"2560519006","title":"福泰制药（VKTX）跌43.19%最近五个交易日迄今累计下跌41.18%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2560519006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560519006?lang=zh_cn&edition=full","pubTime":"2025-08-19 22:54","pubTimestamp":1755615291,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","LU0432979614.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","IE00B4R5TH58.HKD","SG9999001176.USD","VRTX","LU0234570918.USD","LU0823416689.USD","LU1585245621.USD","LU2362541273.HKD","BK4532","SG9999013999.USD","BK4585","LU1093756325.SGD","IE0002270589.USD","LU0061475181.USD","LU0256863811.USD","BK4567","LU0109394709.USD","LU2362540622.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","SG9999001176.SGD","LU1035775433.USD","BK4588","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","SGXZ57979304.SGD","LU1093756168.USD","LU1778281490.HKD","LU0079474960.USD","VKTX","LU2236285917.USD","LU1674673428.USD","LU0289739699.SGD","LU2462157665.USD","LU2417539215.USD","LU2237438978.USD","LU0058720904.USD","LU0417517546.SGD","BK4533","LU0320765992.SGD","LU1674673691.USD","IE0009355771.USD","IE00B19Z9P08.USD","BK4139","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"1131183701","title":"异动解读 | Viking Therapeutics盘中大跌40%，口服减肥药临床试验结果不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1131183701","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131183701?lang=zh_cn&edition=full","pubTime":"2025-08-19 21:33","pubTimestamp":1755610398,"startTime":"0","endTime":"0","summary":"8月19日周二，生物制药公司Viking Therapeutics 股价盘中大跌40.62%，引发市场广泛关注。此次暴跌主要源于该公司公布的口服减肥药VK2735中期临床试验结果不及预期。据公司声明，在为期13周的中期试验中，VK2735帮助患者最多减重12.2%。这一结果打击了投资者对Viking Therapeutics能够在竞争激烈的减肥药市场上与行业巨头礼来和诺和诺德抗衡的信心。相比之下，礼来公司最近公布的口服减肥药orforglipron在72周试验中实现了12.4%的减重效果，而诺和诺德的口服semaglutide在68周内达到了15%的减重率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":1},{"id":"2560419481","title":"由于Viking Therapeutics(VKTX.US)旗下实验性口服减肥药的中期试验数据不及预期截至发稿该股周二美","url":"https://stock-news.laohu8.com/highlight/detail?id=2560419481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560419481?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:57","pubTimestamp":1755608270,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LLY","LU0106261372.USD","LU0122379950.USD","LU0943347566.SGD","LU1093756325.SGD","LU2237443622.USD","LU0097036916.USD","LU0109394709.USD","LU0316494557.USD","LENZ","LU0823434740.USD","LU1720051017.SGD","LU1917777945.USD","LU1988902786.USD","SG9999014914.USD","VKTX","GIPR","LU2265009873.SGD","LU2456880835.USD","LU0882574139.USD","LU0820561909.HKD","SG9999013999.USD","LU0354030511.USD","BK4581","LU2023250504.SGD","SG9999015978.USD","LU1868837300.USD","LU2462157665.USD","LU1983299246.USD","LU2237438978.USD","SG9999001176.USD","LU1868836591.USD","161027","BK4144","IE00BFTCPJ56.SGD","LU2552382215.SGD","LU2602419157.SGD","LU2491050071.SGD","LU2491050154.USD","NVO","GLP","LU1974910355.USD","LU0882574055.USD","LU2461242641.AUD","LU0114720955.EUR","LU2063271972.USD","LU2237443895.HKD","LU0385154629.USD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2560191248","title":"美股异动｜公布口服肥胖症药物最新实验数据后，Viking Therapeutics盘前大跌超34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560191248","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560191248?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:56","pubTimestamp":1755608200,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","VKTX","LENZ","BK4585","BK4599","BK4588","BK4007","BK4539"],"gpt_icon":0},{"id":"2560914521","title":"Viking(VKTX.US)盘前暴跌！口服减肥药VK2735中期试验结果不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2560914521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560914521?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:50","pubTimestamp":1755607814,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJT1NW94.SGD","BK4599","LU1093756325.SGD","LU2468319806.SGD","IE00B1BXHZ80.USD","161027","LU2462157665.USD","IE00B4R5TH58.HKD","SG9999014914.USD","LU1023059063.AUD","LU1868836914.USD","LU2471134952.CNY","BK4139","LENZ","LU0708995401.HKD","LU2361044865.SGD","LU1069344957.HKD","LU1988902786.USD","LU2106854487.HKD","LU1232071149.USD","BK4144","LU0114720955.EUR","LU0198837287.USD","IE00BJJMRZ35.SGD","LU0471298777.SGD","LU0820561909.HKD","LU0823434583.USD","SG9999001176.USD","SG9999015952.SGD","LU2491049909.HKD","LU0122379950.USD","GLP","LU2023250504.SGD","GIPR","GB00BDT5M118.USD","LU1127390331.HKD","LU2237443382.USD","LU0289739699.SGD","LLY","LU2237443978.SGD","VKTX","LU2461242641.AUD","LU2471134879.HKD","LU1035775433.USD","LU2602419157.SGD","NVO","LU0471298694.HKD","LU0323591593.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"1157008689","title":"盘前异动｜Viking Therapeutics跌超30%，口服减肥药试验数据低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1157008689","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157008689?lang=zh_cn&edition=full","pubTime":"2025-08-19 20:31","pubTimestamp":1755606697,"startTime":"0","endTime":"0","summary":"盘前异动 | $Viking(VKTX)$ Therapeutics跌超30%，消息方面：公司口服减肥药的研究试验数据不及预期。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9ff65529c8e2f841b9c70653800ff88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","VKTX","BK4539","BK4588","BK4139","BK4585","BK4007"],"gpt_icon":0},{"id":"2557787675","title":"Viking Therapeutics, Inc.盘中异动 早盘股价大涨5.01%报37.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557787675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557787675?lang=zh_cn&edition=full","pubTime":"2025-08-08 22:33","pubTimestamp":1754663586,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日22时33分，Viking Therapeutics, Inc.股票出现波动，股价快速拉升5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.73%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808223307973bfbdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808223307973bfbdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4599","BK4139","BK4585","BK4588","BK4539","BK4007","VKTX"],"gpt_icon":0},{"id":"2555029842","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555029842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555029842?lang=zh_cn&edition=full","pubTime":"2025-07-31 02:35","pubTimestamp":1753900519,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日02时35分，Viking Therapeutics, Inc.股票出现波动，股价大幅拉升5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.91%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731023520a6ca1c56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731023520a6ca1c56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LENZ","VKTX","BK4139","BK4588","BK4007","BK4585","BK4539"],"gpt_icon":0},{"id":"1188474416","title":"维京2025财年Q2业绩会总结及问答精华：肥胖治疗新药进展显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1188474416","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188474416?lang=zh_cn&edition=full","pubTime":"2025-07-24 18:32","pubTimestamp":1753353135,"startTime":"0","endTime":"0","summary":"未来计划包括继续推进VK2735的3期临床试验，并在2025年第四季度提交针对淀粉样受体激动剂项目的新药研究申请。净亏损为6560万美元，每股亏损0.58美元，而去年同期净亏损为2230万美元，每股亏损0.20美元。问题4：在3期Vanquish试验中，您有一个17.5毫克的最高剂量。此外，安慰剂组患者在试验结束后有资格进入开放标签延长期。我们计划在今年第四季度向FDA提交IND申请。维京公司在2025财年第二季度取得了显著进展，特别是在VK2735肥胖治疗项目的临床试验中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"gpt_icon":1},{"id":"2553320517","title":"Viking Therapeutics, Inc.2025财年第二财季实现净利润-65.56百万美元，同比减少194.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553320517","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553320517?lang=zh_cn&edition=full","pubTime":"2025-07-24 17:00","pubTimestamp":1753347625,"startTime":"0","endTime":"0","summary":"7月24日，Viking Therapeutics, Inc.公布财报，公告显示公司2025财年第二财季净利润为-65.56百万美元，同比减少194.65%；其中营业收入为0.00美元，每股基本收益为-0.58美元。从资产负债表来看，Viking Therapeutics, Inc.总负债32.39百万美元，其中短期债务468000.00美元，资产负债比为0.26，流动比率为0.26。机构评级：截至2025年7月24日，当前有19家机构对Viking Therapeutics, Inc.目标价做出预测，其中目标均价为89.58美元，其中最低目标价为30.00美元，最高目标价为125.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724172632a460fdbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724172632a460fdbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VKTX"],"gpt_icon":0},{"id":"1136970098","title":"异动解读 | Viking Therapeutics盘前大跌8.2%，季度亏损远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1136970098","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136970098?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:14","pubTimestamp":1753344865,"startTime":"0","endTime":"0","summary":"生物制药公司Viking Therapeutics, Inc.今日盘前大跌8.2%，主要受到公司最新季度财报不及预期的影响。这一跌幅远超昨日夜盘5.36%的跌幅，反映出投资者对公司财务状况的担忧程度进一步加深。根据公司公布的财报，截至6月30日的季度，Viking Therapeutics调整后每股亏损为58美分，远超分析师平均预期的45美分亏损。尽管Viking Therapeutics在生物技术领域有着潜力巨大的研发管线，但持续的巨额亏损引发了投资者对公司短期财务状况的担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":0},{"id":"1131694288","title":"异动解读 | Viking Therapeutics季度亏损超预期，夜盘股价大跌5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131694288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131694288?lang=zh_cn&edition=full","pubTime":"2025-07-24 08:02","pubTimestamp":1753315372,"startTime":"0","endTime":"0","summary":"生物制药公司Viking Therapeutics, Inc.在夜盘交易中股价大跌5.36%，引发投资者关注。这一跌幅主要受到公司最新季度财报不及预期的影响。根据公司公布的财报，截至6月30日的季度，Viking Therapeutics调整后每股亏损为58美分，远超分析师平均预期的45美分亏损。尽管Viking Therapeutics在生物技术领域有着潜力巨大的研发管线，包括VK2809、VK5211和VK0214等产品，但持续的巨额亏损似乎引发了投资者对公司短期财务状况的担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VKTX"],"gpt_icon":0},{"id":"1153521511","title":"这些美股股票本周或随财报发布而大幅波动","url":"https://stock-news.laohu8.com/highlight/detail?id=1153521511","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153521511?lang=zh_cn&edition=full","pubTime":"2025-07-22 12:00","pubTimestamp":1753156846,"startTime":"0","endTime":"0","summary":"第二季度财报季似乎开局良好，标普500指数成分股中已有12%发布财报。展望未来，这些股票本周可能因最新季度业绩而表现突出的股票，具体通过分析期权市场活动预测其潜在波动幅度。这家休闲快餐卷饼连锁店将于本周三公布业绩，股价可能因此波动6%。西南航空该股年内上涨10%，本周三公布最新季度财报后股价可能波动5%，公司将于次日召开财报电话会议。$特许通讯 $这家电信公司股价今年上涨13%，财报公布后（本周五）可能波动7%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/61928afb8d779fedee3e8c2bb8802198","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/61928afb8d779fedee3e8c2bb8802198"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DECK","GM","DHR","VKTX","INTC","ENPH","LUV","URI","GOOGL","T"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0473},{"period":"1month","weight":0.057},{"period":"3month","weight":0.4288},{"period":"6month","weight":0.3852},{"period":"1year","weight":-0.2271},{"period":"ytd","weight":-0.042}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。公司的主导临床程序是VK0612，它是进入2b期临床试验为2型全球最大的健康挑战之一的治疗糖尿病疾病口服药物，它在同药物中排列第一。公司的第二临床程序vk5211，可把口服的候选药物送入第二阶段临床试验治疗一种复杂的疾病特点的不受控制的肌肉质量下降癌症恶病。VK5211是一种非甾体选择性雄激素受体调节剂，或SARM。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010029},{"month":2,"riseRate":0.5,"avgChangeRate":0.226268},{"month":3,"riseRate":0.3,"avgChangeRate":-0.034371},{"month":4,"riseRate":0.5,"avgChangeRate":0.019074},{"month":5,"riseRate":0.272727,"avgChangeRate":0.07927},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.022105},{"month":7,"riseRate":0.545455,"avgChangeRate":0.01621},{"month":8,"riseRate":0.454545,"avgChangeRate":0.012248},{"month":9,"riseRate":0.272727,"avgChangeRate":0.053956},{"month":10,"riseRate":0.363636,"avgChangeRate":0.052351},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.018186},{"month":12,"riseRate":0.636364,"avgChangeRate":0.151761}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}